Cipla Share Price Target 2026: Analyst Forecast, Bull & Bear Case

Thu Apr 09 2026

Cipla (NSE: CIPLA) is trading at Rs 1,420 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Cipla share price target stands at Rs 1,650-1,850 — implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term share price targets.

Table of Contents

Current Price Overview

Metric	Value
Current Market Price (CMP)	Rs 1,420
52-Week High	undefined
52-Week Low	undefined
Market Cap	Rs 1,14,600 Cr
P/E Ratio	26x
12M Analyst Target	Rs 1,650-1,850
Bull Case	Rs 2,100
Bear Case	Rs 1,050

About Cipla

Click Here – Get Free Investment Predictions

Cipla (NSE: CIPLA) is a leading listed company in the Pharma sector with a market capitalisation of Rs 1,14,600 Cr. The company operates across its core business segments and is well-positioned for the Indian economic growth cycle.

Key Catalysts Driving Cipla Share Price

1. US Peptide and Complex Generics Pipeline

2. Cipla’s US complex generics pipeline — inhalers, injectables, and peptides — is the most advanced among Indian mid-cap pharma. Approvals for Advair Diskus (fluticasone/salmeterol), Abraxane biosimilar (paclitaxel), and GLP-1 peptide generics are multi-year revenue growth drivers.

3. India Respiratory Leadership — Seretide and Combimist

4. Cipla holds the leadership position in India’s branded respiratory drug market. Seretide (fluticasone) and Combimist (salbutamol+ipratropium) have no generic threat and grow at 12-15% annually.

5. South Africa Business Recovery

6. Cipla’s South Africa business (pharmaceutical distribution and branded generics) is recovering as rand stabilises and private healthcare demand grows. South Africa contributes approximately 10% of revenue.

7. Cipla Foundation — Quality and Affordability Brand

8. Cipla’s 90-year brand in India — built on making AIDS drugs affordable in Sub-Saharan Africa — commands patient and doctor trust that private label peers cannot replicate.

Key Risks to Cipla Share Price

US inhaler generic approval delays from FDA:

South Africa rand depreciation:

India branded margin compression:

Promoter holding below 40% creating governance questions:

The 26% US reciprocal tariff on Indian goods — announced April 2, 2026 — has created a macro overhang affecting all Indian equities through FII outflows and earnings estimate revisions. Resolution of tariff uncertainty would be a meaningful positive catalyst for re-rating.

Technical Analysis and Support Levels

Cipla is trading at Rs 1,420 vs. a 52-week range of undefined to undefined. Key technical support is at Rs 1,350-1,520. The 200-day moving average provides medium-term guidance for trend direction.

Download the Univest iOS App or Univest Android App to track Cipla’s live price and get daily research insights.

Latest Quarterly Financial Performance

Key Metric	Latest Quarter	Year-Ago Quarter	YoY Change
Revenue	Rs 7,073 Cr	Rs 6,429 Cr	+10.0%
Net Profit	Rs 1,571 Cr	Rs 1,242 Cr	+26.5%
EBITDA Margin	26.0%	24.2%	+180 bps
US Revenue	Rs 2,384 Cr	Rs 2,122 Cr	+12.3%

Track Cipla’s live financials on Univest Screener

Institutional Positioning — FII, DII, Promoter

Promoter holds 33.5%. FII holding is 20.4% and DII holds 16.8%. Institutional holding trends are a critical leading indicator for price direction. Rising FII holding typically precedes price recovery; declining FII signals ongoing caution. Track institutional flow changes on Univest Screener.

Cipla Share Price Target 2026

Subscribe to Univest Pro for Premium Stock Research and F&O Setups

Short-Term Target (3–6 Months)

Short-term support and trading range: Rs 1,350-1,520. In the near term, the stock is likely to remain in this band pending clarity on Q4 FY26 results and FY27 guidance. Any macro positive from India-US tariff negotiations would accelerate a move toward the upper end of this range.

12-Month Analyst Target

The 12-month analyst consensus for Cipla is Rs 1,650-1,850. The bear case — if FY27 guidance disappoints or macro headwinds intensify — is Rs 1,050. The bull case — on full earnings delivery and macro recovery — is Rs 2,100. These are analyst estimates based on publicly available data and may differ materially from actual price performance.

Long-Term Target (2027–2028)

For 2027-2028, analysts project Cipla toward the Rs 2,200-2,600 range — assuming FY27 guidance delivery and normalisation of macro headwinds. Track live targets on Univest Screener.

Conclusion

The Cipla share price target for 2026 is Rs 1,650-1,850 based on analyst consensus. The bear case is Rs 1,050 and the bull case is Rs 2,100. At Rs 1,420, Cipla is trading at 26x P/E with market cap of Rs 1,14,600 Cr. Whether this is a buy depends on your risk tolerance, investment horizon, and portfolio context. For more share price target analysis, visit

Univest Blogs

Disclaimer: This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

FAQs

Q1. What is Cipla share price target for 2026?

The 12-month analyst consensus is Rs 1,650-1,850. Bull case: Rs 2,100. Bear case: Rs 1,050.

Q2. Is Cipla a good buy at Rs 1,420?

At 26x P/E and Rs 1,420, Cipla offers potential recovery to Rs 1,650-1,850 over 12 months. Consult a SEBI-registered financial advisor before investing.

Q3. What are the key risks for Cipla?

Key risks include macro headwinds from US tariffs, sector-specific challenges, and any guidance miss in Q4 FY26 results. Monitor institutional holding trends on Univest Screener.

Q4. What is Cipla long-term share price target?

Long-term target for FY28 is Rs 2,200-2,600, contingent on sustained earnings delivery and macro recovery.